U.S. markets closed

Glaukos Corporation (GKOS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
91.75+1.18 (+1.30%)
At close: 4:00PM EDT

91.75 +0.05 (0.05%)
After hours: 4:16PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close90.57
Open91.26
Bid92.36 x 1100
Ask92.32 x 800
Day's Range89.81 - 93.10
52 Week Range34.10 - 99.00
Volume228,952
Avg. Volume407,821
Market Cap4.201B
Beta (5Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-2.70
Earnings DateMay 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est88.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia

    Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into an amended licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform (the Eyelid Drug Delivery Platform) for application in the treatment of presbyopia.

  • Business Wire

    Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5

    Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 5, 2021.

  • Why Is Glaukos (GKOS) Down 7.1% Since Last Earnings Report?
    Zacks

    Why Is Glaukos (GKOS) Down 7.1% Since Last Earnings Report?

    Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.